Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 6/2006

01-12-2006 | Original Article

Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase

Authors: Muhammad Wasif Saif, Glenda Black, Martin Johnson, Suzanne Russo, Robert Diasio

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2006

Login to get access

Abstract

Background: The first reported case of radiation (XRT) recall related to capecitabine described dermatitis in a previously radiated field in a breast cancer patient (Ortman; JCO). We previously reported the first case of recall syndrome manifesting as diffuse gastritis and duodenitis related to capecitabine with prior XRT with 5-FU in a pancreatic cancer patient (Saif; JARCET). We report here another pancreatic cancer patient with a radiation recall receiving capecitabine following capecitabine-XRT. Patients and methods: From April 2004 to June 2005, 20 patients with locally advanced pancreatic adenocarcinoma were treated with capecitabine 1,600 mg/m2 daily with concomitant radiation (5040cGy) Monday–Friday (weekends off) for a total of 6 weeks, followed by capecitabine 2,000 mg/m2 daily for 14 days every 3 weeks. One male patient with tumor in the neck and body of pancreas and not infiltrating the duodenum dropped hemoglobin to 7.3 g/dl at the end of the ninth week, and melena on rectal examination. Specimen of primary pancreatic ductal adenocarcinoma was obtained via EUS-guided biopsy before starting XRT on day 1 and utilized for RNA extraction. TP mRNA level was determined by real-time quantitative PCR (RT-Q-PCR). Results: Upper endoscopy revealed gastritis consistent with radiation toxicity. Colonoscopy was negative. Transfusion of three units of packed red blood cells (PRBCs) was given. The dose of capecitabine was reduced by 25%. His anemia continued to progress, a CT scan revealed 39% decrease in the tumor size (PR). Analysis of tumor specimen prior to the start of capecitabine-XRT showed TP expression of 183.16 (high). In addition to TP, DPD was 7.40, and TNF-alpha 4,114.56. Conclusion: We believe this case to be the second case of radiation recall presenting as diffuse gastritis in a patient receiving capecitabine after previous treatment with XRT. Further studies, including the role of TP are warranted into the pathogenesis of this unique phenomenon.
Literature
1.
go back to reference Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6,000 Rads) radiation alone, moderate dose radiation (4,000 Rads +5-Fluorouracil), and high dose radiation + 5-Fluorouracil. Cancer 48:1705–1710PubMedCrossRef Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6,000 Rads) radiation alone, moderate dose radiation (4,000 Rads +5-Fluorouracil), and high dose radiation + 5-Fluorouracil. Cancer 48:1705–1710PubMedCrossRef
2.
go back to reference Earle CC, Agboola O, Maroun J et al (2003) The treatment of locally advanced pancreatic cancer: a practice guideline. Can J Gastroenterol 17(3):161–167PubMed Earle CC, Agboola O, Maroun J et al (2003) The treatment of locally advanced pancreatic cancer: a practice guideline. Can J Gastroenterol 17(3):161–167PubMed
3.
go back to reference Crane CH, Janjan NA, Evans DB et al (2001) Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29(1):9–18PubMed Crane CH, Janjan NA, Evans DB et al (2001) Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29(1):9–18PubMed
4.
go back to reference Ishikawa T, Utoh M, Sawada N et al (1998) Tumor selective delivery of 5-fluoropyrimidine by capcetibine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091–1097CrossRefPubMed Ishikawa T, Utoh M, Sawada N et al (1998) Tumor selective delivery of 5-fluoropyrimidine by capcetibine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091–1097CrossRefPubMed
5.
go back to reference Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097–4106PubMed Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097–4106PubMed
6.
go back to reference Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160–164CrossRefPubMed Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160–164CrossRefPubMed
7.
go back to reference Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMed Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMed
8.
go back to reference Camidge R, Price A (2001) Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 59:237–245CrossRefPubMed Camidge R, Price A (2001) Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 59:237–245CrossRefPubMed
9.
go back to reference Burdon J, Bell R, Sullivan J et al (1978) Adriamycin induced recall phenomenon fifteen years after radiotherapy. JAMA 239:931CrossRefPubMed Burdon J, Bell R, Sullivan J et al (1978) Adriamycin induced recall phenomenon fifteen years after radiotherapy. JAMA 239:931CrossRefPubMed
10.
go back to reference Phillips KA, Urch M, Bishop JF (1995) Radiation recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 13:305PubMed Phillips KA, Urch M, Bishop JF (1995) Radiation recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 13:305PubMed
11.
go back to reference Fontana JA (1979) Radiation recall associated with VP-16–213 therapy. Cancer Treat Rep 63(2):224–225PubMed Fontana JA (1979) Radiation recall associated with VP-16–213 therapy. Cancer Treat Rep 63(2):224–225PubMed
12.
go back to reference Burstein H (2000) Radiation recall dermatitis from gemcitabine. J Clin Oncol 18:693–994PubMed Burstein H (2000) Radiation recall dermatitis from gemcitabine. J Clin Oncol 18:693–994PubMed
13.
go back to reference Von Essen CF, Kligerman MM, Calabresi P (1963) Radiation and 5-fluorouracil: a controlled clinical study. Radiology 81:1018–1026PubMed Von Essen CF, Kligerman MM, Calabresi P (1963) Radiation and 5-fluorouracil: a controlled clinical study. Radiology 81:1018–1026PubMed
14.
go back to reference Ortmann E, Hohenberg G (2002) Treatment side effects Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol 20:3029–3030PubMed Ortmann E, Hohenberg G (2002) Treatment side effects Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol 20:3029–3030PubMed
15.
go back to reference Jeffrey G, Truss C, Saif MW (2004) Radiation recall syndrome associated with capecitabine. J Appl Res 4:495–498 Jeffrey G, Truss C, Saif MW (2004) Radiation recall syndrome associated with capecitabine. J Appl Res 4:495–498
16.
go back to reference Blanquicett C, Saif MW, Buchsbaum D, Eloubeidi M, Vickers S, Chhieng D, Carpenter M, Russo S, Sellers J, Diasio R, Johnson MR (2005) Antitumor efficacy of capecitabine and celecoxib in irradiated and lead shielded, contralateral human BxPC-3 pancreatic xenografts: clinical implications of abscopal effects in a metastatic model. Clin Cancer Res (accepted) Blanquicett C, Saif MW, Buchsbaum D, Eloubeidi M, Vickers S, Chhieng D, Carpenter M, Russo S, Sellers J, Diasio R, Johnson MR (2005) Antitumor efficacy of capecitabine and celecoxib in irradiated and lead shielded, contralateral human BxPC-3 pancreatic xenografts: clinical implications of abscopal effects in a metastatic model. Clin Cancer Res (accepted)
17.
go back to reference Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR (2002) Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther 1:1139–1145PubMed Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR (2002) Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther 1:1139–1145PubMed
18.
go back to reference Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB (2000) Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278(2):175–184CrossRefPubMed Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB (2000) Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278(2):175–184CrossRefPubMed
19.
go back to reference Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K et al (1992) Angiogenic factor. Nature 356:668CrossRefPubMed Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K et al (1992) Angiogenic factor. Nature 356:668CrossRefPubMed
20.
go back to reference Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5:2948–2953PubMed Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5:2948–2953PubMed
21.
go back to reference Lin E, Morris JS, Ayers GD (2002) Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 16(12 Suppl No 14):31–37 Lin E, Morris JS, Ayers GD (2002) Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 16(12 Suppl No 14):31–37
22.
go back to reference Blanquicett C, Buchsbaum DJ, Vickers SM, Sellers JC, Carpenter M, Diasio RB, Johnson MR (2003) Rationale for capecitabine and irradiation to treat pancreatic cancer. Proc Am Soc Clin Oncol 22:241 (abstract 966) Blanquicett C, Buchsbaum DJ, Vickers SM, Sellers JC, Carpenter M, Diasio RB, Johnson MR (2003) Rationale for capecitabine and irradiation to treat pancreatic cancer. Proc Am Soc Clin Oncol 22:241 (abstract 966)
23.
go back to reference Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23(34):8679–8687CrossRefPubMed Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23(34):8679–8687CrossRefPubMed
24.
go back to reference Tamaki M, Saito R, Ogawa O, Yoshimura N, Ueda T (2004) Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors. J Urol 172(3):945–948CrossRefPubMed Tamaki M, Saito R, Ogawa O, Yoshimura N, Ueda T (2004) Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors. J Urol 172(3):945–948CrossRefPubMed
25.
go back to reference Saif MW, Joseph M, Tang S, Vickers S, Plants B, Russo S (2004) Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer. J Appl Res 4(4):635–646 Saif MW, Joseph M, Tang S, Vickers S, Plants B, Russo S (2004) Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer. J Appl Res 4(4):635–646
26.
go back to reference Crane CH, Ellis LM, Abbruzzese JL, Douglas EB, Henry X, Ho L, Tamm EM, Chaan N, O’Reilly M, Wolff RA (2005) Phase I trial of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic adenccarcinoma. In: Proceedings of ASCO 2005 (abstract: 4033) Crane CH, Ellis LM, Abbruzzese JL, Douglas EB, Henry X, Ho L, Tamm EM, Chaan N, O’Reilly M, Wolff RA (2005) Phase I trial of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic adenccarcinoma. In: Proceedings of ASCO 2005 (abstract: 4033)
Metadata
Title
Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase
Authors
Muhammad Wasif Saif
Glenda Black
Martin Johnson
Suzanne Russo
Robert Diasio
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0223-8

Other articles of this Issue 6/2006

Cancer Chemotherapy and Pharmacology 6/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine